A Phase II trial of Atezolizumab (anti-PDL1) with Carboplatin in Patients with Metastatic Triple Negative Breast Cancer

Study Overview

The purpose of this study is to test how well the combination of study drugs, carboplatin and atezolizumab, keeps metastatic triple negative breast cancer from growing compared to taking carboplatin only.

Study Description

This is an interventional randomized phase II trial studies how well carboplatin with or without atezolizumab works in treating patients with stage IV triple negative breast cancer.

Additional Information

Participants will not be paid for their participation.

  • IRB Number: 1710788954 (TBCRC043)
  • Research Study Identifier: TX8616
  • Principal Investigator: Tarah Ballinger, MD

Recruitment Status


Contact the research team to learn more about this study.

Fields marked with asterisk (*) are required

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Volunteer Sign up

Volunteer Registry

Create your profile and be matched to research opportunities

Register Now!

Contact Us

If you need help finding a study or have any questions, please contact us at inhealth@iu.edu or by phone at (888) 264-0005.